Anti-B. anthracis toxin Recombinant Antibody (1A5) (CAT#: MRO-090CT)

Recombinant monoclonal antibody specifically binds to and neutralizes the protective antigen of Bacillus anthraci. Antibody 1A5 is specific for epitopes residing in the PA63 domain of the PA molecule.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
Neut

Figure 1 Neutralization of anthrax LT by human PA-specific monoclonal antibodies.

Figure 1 Neutralization of anthrax LT by human PA-specific monoclonal antibodies.

CHO-derived antibodies specific for PA were preincubated with fixed amounts of PA and LF prior to their addition to cultures of RAW 264.7 cells. Cell viability was determined approximately 16 h later, and the degree to which the added antibody blocked toxicity was determined. The domain specificity (PA₂₀, PA₆₃, or domain 4) is indicated for each clone.

Reason, D., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2009). Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infection and immunity, 77(5), 2030-2035.

ELISA

Figure 2 Domain-specific inhibition of antibody-mediated toxin neutralization by preincubation with PA or its amino-terminal fragment in a solid-phase ELISA.

Figure 2 Domain-specific inhibition of antibody-mediated toxin neutralization by preincubation with PA or its amino-terminal fragment in a solid-phase ELISA.

Toxin-neutralizing antibodies were preincubated with a receptor-deficient mutant of PA (PArb−) or the amino-terminal 191 residues of PA expressed as a GFP fusion protein (PA₂₀-GFP) prior to their addition to the RAW267.4 cytotoxicity assay mixture. Open bars represent the degree of inhibition observed when antibodies were preincubated with PArb−. Filled bars represent inhibition by PA₂₀-GFP. Antibodies are grouped by their domain specificity.

Reason, D., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2009). Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infection and immunity, 77(5), 2030-2035.

Cyt

Figure 3 Relative toxin-neutralizing ability of PA₆₃- or PA₂₀-specific antibodies.

Figure 3 Relative toxin-neutralizing ability of PA₆₃- or PA₂₀-specific antibodies.

CHO-derived human antibodies specific for PA were titrated in the RAW 264.7 cytotoxicity assay and the amount required to bring about 50% cell death determined. The median value for each group is indicated by a horizontal line. PA₆₃- and PA₂₀-specific antibodies differed significantly in the concentration required to effect 50% neutralization of LT (P = 0.01 by the Mann-Whitney U test).

Reason, D., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2009). Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infection and immunity, 77(5), 2030-2035.

Funcs

Figure 4 Furin proteolysis of ¹²⁵I-PA in vitro.

Figure 4 Furin proteolysis of ¹²⁵I-PA in vitro.

PA pre-incubated with PA₆₃-specific neutralizing antibody 1A5.

Reason, D., Liberato, J., Sun, J., Camacho, J., & Zhou, J. (2011). Mechanism of Lethal Toxin Neutralization by a Human Monoclonal Antibody Specific for the PA20 Region of Bacillus anthracis Protective Antigen. Toxins, 3(8), 979-990.


Specifications

  • Immunogen
  • PA protein of B. anthracis
  • Host Species
  • Human
  • Type
  • Human antibody
  • Specificity
  • B. anthracis
  • Species Reactivity
  • B. anthracis
  • Clone
  • 1A5
  • Applications
  • Neut, ELISA, Cyt, Funcs, WB
  • Related Disease
  • Anthrax (Bacillus anthracis)

Applications

  • Application Notes
  • The B. anthracis toxin antibody has been reported in applications of Neutralization, Enzyme-linked Immunosorbent Assay, Cytotoxicity, Functional Assay, Western Blot.

Target

  • Alternative Names
  • Bacillus anthracis toxin; Anthrax toxin; Bacillus anthracis; B. anthracis

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 1A5"

See other products for "B. anthracis Toxin"

Human Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-090CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare